Anpheros Search · Treatment

Ibandronic acid

Also known as: Bondronat · Bonviva · Ibandronic Acid Teva · Iasibon · Ibandronic acid Accord

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, ibandronic acid is indicated for the prevention of skeletal events, such as pathological fractures or bone complications requiring radiotherapy or surgery, in patients with breast cancer and bone metastases. It is also indicated in the European Union for the treatment of tumour-induced hypercalcaemia with or without metastases. Additionally, in the European Union, it is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture, where a reduction in the risk of vertebral fractures has been demonstrated but efficacy on femoral neck fractures has not been established.

Source: European Medicines Agency (EMA), Bondronat — EPAR, 16/09/2024. © European Medicines Agency. · Source: European Medicines Agency (EMA), Bonviva — EPAR, 16/09/2024. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

EMA
EMEA/H/C/000101, EMEA/H/C/000501, EMEA/H/C/001195, EMEA/H/C/002025, EMEA/H/C/002638

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Bondronat

Bondronat is indicated for: prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases; treatment of tumour-induced hypercalcaemia with or without metastases.

Source: European Medicines Agency (EMA), Bondronat — EPAR, 16/09/2024. © European Medicines Agency.

Document date: 16/09/2024 · Official document →

EMA (EU) Bonviva

Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

Source: European Medicines Agency (EMA), Bonviva — EPAR, 16/09/2024. © European Medicines Agency.

Document date: 16/09/2024 · Official document →

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Ibandronic acid approved for in the European Union?

Bondronat is indicated for: prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases; treatment of tumour-induced hypercalcaemia with or without metastases. (Source: European Medicines Agency (EMA), Bondronat — EPAR, 16/09/2024. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Bondronat — EPAR, 16/09/2024. © European Medicines Agency.
  • Source: European Medicines Agency (EMA), Bonviva — EPAR, 16/09/2024. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →